World OTC Pharmaceutical Market 2012-2022

June 2012 | 147 pages | ID: G9F241F63D5EN
Visiongain

Abstracts

Report Details

Discover the highest potential revenues in over-the-counter medicine

What does the future hold for OTC medicines? Visiongain's report shows you potential revenues to 2022, assessing data, trends, opportunities and prospects there.

This new study investigates OTC (over-the-counter) pharmaceuticals: medicines sold without prescriptions. It lets you assess projected sales at world market, therapeutic submarket, product and national level to 2022. You discover high growth potential there.

You see forecasting of five world-level submarkets to 2022, finding potential revenues

• Analgesics/pain relievers
• Gastrointestinal agents
• Dermatological treatments
• Smoking cessation products
• Other relevant sales in consumer healthcare.

The analyses exclude vitamins, minerals and other nutritional products.

Also, how will eight leading products - including Tylenol, Nicorette, Panadol and Advil - perform from 2012 to 2022? Our investigation gives you business research and analysis with sales forecasts, including revenues for three leading OTC brand portfolios to 2022.

You find discussion of manufacturing and distribution of OTC pharmaceuticals. We also discuss regulations in main regions - the US, Europe, Japan and other places.

Our report lets you assess Rx-to-OTC switching too. You see trends and outlooks for line extensions of prescription drugs

• Cough, cold and allergies
• Pain relief, including arthritis pains
• Gastrointestinal disorders
• Dermatological conditions
• Obesity and weight loss
• Oral contraceptives
• Cholesterol lowering
• Triptans
• Erectile dysfunction
• Sleep disorders.

We discuss other aspects of the industry and market, including Web 2.0 marketing. You find discussions of brand identity and private labels, as well as developments in OTC retail channels, including behind-the-counter and pharmacy-only sales.

Market value for 2014 and future prospects in consumer healthcare

What will happen next? There is a trend for drugs to move from prescription-only to OTC use (Rx-to-OTC switching) in product lifecycle management (PLM).

Overall world revenue for OTC medicines will reach $80.7bn in 2014, our report forecasts. Brand line extensions and PLM will be important, stimulating revenue generation and unit sales worldwide. You see high revenue growth possible to 2022.

From 2012 onwards, Rx-to-OTC switching and emerging healthcare markets - especially in Asia and Latin America - will produce high sales growth and large revenues. The pharma industry will benefit, as will consumers.

There are high levels of self-medication for many ailments. OTC treatments help consumers and healthcare providers reduce medical costs. Our study shows you the potential those products hold.

From 2012 to 2022, the pharmaceutical industry will develop new OTC treatments; our analyses predict strong revenue growth overall. New formulations and generics will be important to the world market. You see opportunities in consumer healthcare.

What are companies doing? Our work profiles 11 organisations, investigating activities and prospects of the industry. You assess these companies

• Johnson & Johnson
• Sanofi
• GlaxoSmithKline
• Novartis
• Bayer
• Pfizer
• Boehringer Ingelheim
• Perrigo
• Merck & Co.
• Reckitt Benckiser
• Procter & Gamble.

Product launches and strong performance from some existing brands will stimulate the market this decade. Marketing and promotional campaigns remain important.

What effects will competition have? Brand extensions and OTC switching will change the industry. Our investigation shows you revenue prospects for OTC markets, leading products and portfolios. Many opportunities remain, with high, fast-rising sales possible to 2022.

Forecasts, market shares, developmental trends, commercial news and discussions

In visiongain's report you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses (SWOT and STEP), company profiles, R&D and commercial developments. You receive 60 tables, 35 charts and two research interviews.

Nine ways World OTC Pharmaceutical Market 2012-2022 helps you

In particular, our study gives you the following knowledge on the topic

• Find potential revenues to 2022 for the overall world market and submarkets
• Discover projected revenues of leading products and OTC portfolios to 2022
• See market forecasting to 2022 for the US, Japan, EU5 countries, China and India
• Assess 11 leading companies, and others, discovering activities and outlooks
• Review prospects for Rx-to-OTC switching by therapeutic area
• Investigate competition and opportunities influencing sales
• Find out what will stimulate and restrain the industry and market
• Analyse prospects for established companies and those seeking to enter the sector
• View opinions from our survey, seeing interviews with authorities.

There, you discover quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed on business intelligence.

Without our report you could miss out on information that your competitors use.

Gain research and analysis now for consumer healthcare

Our study is for everybody needing industry and market analyses for OTC pharma products. You find data, predictions and answers there. Please order that report now.

Contents

1. EXECUTIVE SUMMARY

1.1 Overview of Findings
1.2 Aims, Scope and Format of the Report
  1.2.1 Chapter Outlines
1.3 Research and Analysis Methods

2. INTRODUCTION TO OTC PHARMACEUTICALS

2.1 OTC Medicines
2.2 The Main Features of OTC Pharmaceuticals
2.3 OTC Switching
2.4 Manufacturing and Distribution of OTC Pharmaceuticals
2.5 Regulation of OTC Pharmaceuticals
  2.5.1 Regulation of OTC Pharmaceuticals in the US
  2.5.2 Regulation of OTC Pharmaceuticals in Japan
  2.5.3 Regulation of OTC Pharmaceuticals in Europe
  2.5.4 Regulation of OTC Pharmaceuticals in Other Countries
2.6 Main Classes of OTC Pharmaceuticals
  2.6.1 Analgesics
    2.6.1.1 Internal Analgesics
    2.6.1.2 External Analgesics
  2.6.2 Cough, Cold and Allergy Products
    2.6.2.1 Cough and Cold Remedies
    2.6.2.2 Anti-Allergy OTC Products
  2.6.3 Dermatological Products
    2.6.3.1 Minor Cuts and Wounds
    2.6.3.2 Acne
    2.6.3.3 Rashes, Itchy Skin, Dermatitis and Eczema
    2.6.3.4 Cold Sores
    2.6.3.5 Warts
    2.6.3.6 Fungal Skin Infections
    2.6.3.7 Haemorrhoids
    2.6.3.8 Other Dermatological Products
  2.6.4 Gastrointestinal Products
    2.6.4.1 Indigestion and Heartburn
    2.6.4.2 Anti-Diarrhoea OTC Pharmaceuticals
    2.6.4.3 Laxatives
    2.6.4.4 Anti-Emetic OTC Pharmaceuticals
    2.6.4.5 Anti-Obesity OTC Pharmaceuticals
    2.6.4.6 Smoking Cessation Aids
  2.6.5 Other OTC Pharmaceuticals
  2.6.6 Vitamins, Minerals and Supplements

3. THE OVERALL WORLD OTC PHARMA MARKET, 2012-2022

3.1 The Global OTC Pharmaceutical Market in 2011
3.2 OTC Sales by Category, 2011
  3.2.1 Top-Selling OTC Drug Brands, 2011
  3.2.2 Leading Companies in the OTC Market, 2011
3.3 World OTC Pharmaceutical Market Forecast, 2012-2022
3.4 OTC Pharmaceutical Submarkets: Forecasts, 2012-2022
  3.4.1 Cough, Cold and Allergy Drugs Lead the OTC Market

4. LEADING COMPANIES IN THE OTC PHARMACEUTICAL MARKET, 2012

4.1 Introduction
  4.1.1 Leading OTC Pharmaceutical Manufacturers, 2011
4.2 Johnson & Johnson
  4.2.1 Challenges in 2011
    4.2.1.1 Reorganisation at McNeil
    4.2.1.2 Competitors Will Seek to Consolidate Gains in the US
    4.2.1.3 Johnson & Johnson's OTC Growth Strategy
    4.2.1.4 Expansion in Developing Markets through Acquisitions
  4.2.2 Johnson & Johnson: OTC Sales Forecast, 2012-2022
  4.2.3 Tylenol
    4.2.3.1 Challenges Facing Tylenol
    4.2.3.2 Tylenol Sales Forecast, 2012-2022
  4.2.4 Nicorette
    4.2.4.1 Nicorette (Johnson & Johnson) Sales Forecast, 2012-2022
4.3 Sanofi
  4.3.1 Allegra Rx-to-OTC Switch Boosts Sanofi Allergy Segment
    4.3.1.1 Allegra/Telfast Franchise Faces Generic Competition
4.4 GlaxoSmithKline
  4.4.1 Panadol
    4.4.1.1 Panadol Sales Forecast, 2012-2022
  4.4.2 Alli
  4.4.3 GSK Smoking Cessation Products
    4.4.3.1 GSK Smoking Cessation Products: Sales Forecast, 2012-2022
4.5 Novartis
  4.5.1 Reported Challenges Faced
  4.5.2 Novartis OTC Pharmaceuticals: Sales Forecast, 2012-2022
4.6 Bayer
  4.6.1 Bayer OTC Pharmaceuticals Sales Forecast, 2012-2022
  4.6.2 Bayer Aspirin
    4.6.2.1 Bayer Aspirin: Sales Forecast, 2012-2022
4.7 Pfizer
  4.7.1 Pfizer OTC Pharmaceuticals Sales Forecast, 2012-2022
  4.7.2 Advil
    4.7.2.1 Advil Sales Forecast, 2012-2022
4.8 Boehringer Ingelheim
  4.8.1 Boehringer Ingelheim Shows Focus on OTC Products and Rx-to-OTC Switching
  4.8.2 The Dulcolax Franchise
  4.8.3 Mucosolvan/Laslvan and Other OTC Products
4.9 Perrigo
  4.9.1 Perrigo: The World's Largest Manufacturer of Store-Brand Pharmaceuticals
  4.9.2 Perrigo Benefits from Challenges Faced in the Industry
  4.9.3 Perrigo's R&D and Customised Marketing
  4.9.4 Perrigo Consolidates with Holdings in Orion, Unico and Laboratorios Diba
  4.9.5 Expansion
4.10 Merck & Co.
  4.10.1 Merck and Joint Venture with Johnson & Johnson
  4.10.2 Claritin OTC (Loratadine)
    4.10.2.1 Claritin OTC Sales Forecast: 2012-2022
4.11 Reckitt Benckiser
  4.11.1 Purchase of Paras Pharmaceuticals and Expansion into Developing Markets
  4.11.2 New OTC Products for 2012
  4.11.3 Reckitt Benckiser: OTC Pharmaceuticals Sales Forecast, 2012-2022
4.12 Procter & Gamble
  4.12.1 PGT Healthcare - Procter & Gamble's Joint Venture with Teva
  4.12.2 Procter & Gamble: OTC Pharmaceuticals Sales Forecast, 2012-2022
  4.12.3 Vicks
    4.12.3.1 Vicks: Sales Forecast, 2012-2022
  4.12.4 Prilosec OTC
    4.12.4.1 Prilosec OTC: Sales Forecast, 2012-2022

5. OTC MEDICINES IN LEADING NATIONAL MARKETS, 2012-2022

5.1 Leading National Markets for OTC Medicines in 2011
5.2 Changes in OTC Pharmaceutical Spending in Leading Markets, 2012-2022
  5.2.1 Developing National Markets will Deliver Highest Revenue Growth Over the Forecast Period
5.3 OTC Pharmaceutical Market in the US to 2022
5.4 OTC Pharmaceutical Market in Japan to 2022
5.5 OTC Pharmaceutical Market in Germany to 2022
5.6 OTC Pharmaceutical Market in France to 2022
5.7 OTC Pharmaceutical Market in the UK to 2022
5.8 OTC Pharmaceutical Market in Italy to 2022
5.9 OTC Pharmaceutical Market in Spain to 2022
5.10 OTC Pharmaceutical Market in China to 2022
  5.10.1 Drivers and Restraints for the OTC Market in China
  5.10.2 OTC Market: Forecast, 2012-2022
5.11 OTC Pharmaceutical Market in India to 2022

6. OTC SWITCHING AND PROSPECTS FOR FUTURE OTC DRUGS

6.1 What Motivates OTC Switching?
6.2 Recent OTC Switching Activity
6.3 Future Prospects for OTC Switching
6.4 Cough, Cold and Allergy
  6.4.1 Anti-Histamines
  6.4.2 Clarinex
  6.4.3 Fluticasone
  6.4.4 Nasacort
6.5 Analgesics
6.6 Triptans
  6.6.1 Prospects for OTC Switching of Triptans in the US
6.7 Arthritis Pain
6.8 Gastrointestinal OTC Switching
  6.8.1 H2 Receptor Blockers
  6.8.2 PPIs
    6.8.2.1 Omeprazole
    6.8.2.2 Lansoprazole
    6.8.2.3 Pantoprazole
    6.8.2.4 Esomeprazole
    6.8.2.5 Rabeprazole
6.9 Dermatological Drugs
  6.9.1 Penlac
  6.9.2 BenzaClin
6.10 Anti-Obesity
6.11 Oral Contraceptives
6.12 Cholesterol-Lowering Drugs
  6.12.1 Lipitor
  6.12.2 Zocor Heart Pro in the UK
  6.12.3 Prospects for OTC Statins in the US
  6.12.4 Worldwide Prospects for OTC Statins
6.13 Erectile Dysfunction Drugs
6.14 Sleep Maintenance
  6.14.1 Silenor
6.15 OTC Switching Trends: 2012-2022

7. QUALITATIVE ANALYSIS OF THE OTC DRUGS MARKET, 2012

7.1 SWOT Analysis of the OTC Pharmaceutical Industry and Market
7.2 OTC Switching
7.3 Brand Identity and Private Labels
7.4 Developments in OTC Retail Channels
7.5 Will OTC Move Behind-the-Counter?
7.6 Web 2.0 Marketing Opportunities
7.7 Demographic Factors
  7.7.1 Population Increase and 'Greying' of the World Population
  7.7.2 Developing Countries - Large Market for OTC Products?
  7.7.3 The Worldwide Downturn in Consumer Spending
  7.7.4 Safety Concerns: Misuse and Abuse of OTC Pharmaceuticals
  7.7.5 Safety Concerns
  7.7.6 OTC Drug Misuse
  7.7.7 OTC Drug Abuse
  7.7.8 Impact on the OTC Industry

8. RESEARCH INTERVIEWS FROM OUR SURVEY

8.1 Interview with Professor Daniel Hussar, Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, USA
  8.1.1 Prospects for a Behind-the-Counter Class of OTC Drugs in the US
  8.1.2 Will There Be An Expansion of the De Facto BTC Class in the US?
  8.1.3 Future OTC Switches
  8.1.4 The Prospects for Switching of Statins in the US
  8.1.5 Does OTC Switching for Chronically-Used Drugs Benefit Patients?
  8.1.6 Development of the OTC Sector
  8.1.7 Responses of the FDA
8.2 Interview with Joshua P. Cohen, PhD, Tufts Center for the Study of Drug Development, Boston, Massachusetts, USA
  8.2.1 Prospects for OTC Statins in the US
  8.2.2 Prospects for a Behind-the-Counter Class of OTC Drugs in the US
  8.2.3 Future OTC Switching Categories
  8.2.4 Prospects for Behind-the-Counter Products in the US
  8.2.5 OTC Safety Issues
  8.2.6 Development of the OTC Sector

9. CONCLUSIONS OF OUR STUDY

9.1 The Global OTC Market in 2011
  9.1.1 Leading OTC Categories
  9.1.2 Leading OTC Brands
  9.1.3 Leading OTC Pharmaceutical Manufacturers
  9.1.4 Leading National Markets
9.2 Global OTC Pharmaceutical Market Forecast, 2012-2022
  9.2.1 OTC Growth Drivers
  9.2.2 OTC Switching
  9.2.3 Emerging OTC Markets
9.3 Future OTC Market Dynamics

List Of Tables

LIST OF TABLES

Table 2.1 OTC Internal Analgesic Active Ingredients, 2012
Table 2.2 OTC External Analgesic Active Ingredients, 2012
Table 2.3 OTC Cough, Cold and Allergy Active Ingredients, 2012
Table 2.4 Antifungal OTC Pharmaceutical Active Ingredients, 2012
Table 2.5 Indigestion and Heartburn OTC Pharmaceutical Active Ingredients, 2012
Table 2.6 Anti-Diarrhoea OTC Pharmaceutical Active Ingredients, 2012
Table 2.7 Laxative OTC Pharmaceutical Active Ingredients, 2012
Table 2.8 Smoking Cessation OTC Pharmaceutical Active Ingredients, 2012
Table 3.1 Leading OTC Brands, 2011
Table 3.2 Leading Companies in the OTC Market, 2011
Table 3.3 The Overall World OTC Pharmaceutical Market: Sales Forecast ($m), 2011-2022
Table 3.4 World OTC Pharmaceutical Therapeutic Submarkets: Sales Forecasts ($m), AGRs (%), CAGRs (%), 2011-2017
Table 3.5 World OTC Pharmaceutical Therapeutic Submarkets: Sales Forecasts ($m), AGRs (%), CAGRs (%), 2018-2022
Table 3.6 World Market Shares (%) for Leading OTC Pharmaceutical Categories, 2011, 2017 and 2022
Table 4.1 Johnson & Johnson OTC Brands, 2012
Table 4.2 Tylenol: Sales Forecast ($m), AGR (%), CAGR (%), 2011-2022
Table 4.3 Tylenol Products, 2012
Table 4.4 Nicorette (Johnson & Johnson) Formulations, 2012
Table 4.5 Nicorette (Johnson & Johnson): Sales Forecast ($m), AGR (%), CAGR (%), 2011-2022
Table 4.6 Prominent GSK OTC Brands, 2012
Table 4.7 Panadol Formulations, 2012
Table 4.8 Panadol: Sales Forecast ($m), AGR (%), CAGR (%), 2011-2022
Table 4.9 GSK Smoking Cessation Brands, 2012
Table 4.10 GSK Smoking Cessation Brands: Sales Forecast ($m), AGR (%), CAGR (%), 2011-2022
Table 4.11 Novartis OTC Brands, 2012
Table 4.12 Bayer OTC Brands, 2012
Table 4.13 Bayer: OTC Pharmaceuticals Sales Forecast ($m), AGR (%), CAGR (%), 2011-2022
Table 4.14 Bayer Aspirin: Sales Forecast ($m), AGR (%), CAGR (%), 2011-2022
Table 4.15 Advil: North American Formulations, 2012
Table 4.16 Advil: Sales Forecast ($m), AGR (%), CAGR (%), 2011-2022
Table 4.17 Boehringer Ingelheim OTC Brands, 2012
Table 4.18 Merck & Co. OTC Brands, 2012
Table 4.19 Claritin OTC: Sales Forecast ($m), AGR (%), CAGR (%), 2011-2022
Table 4.20 Reckitt Benckiser OTC Brands, 2012
Table 4.21 Procter & Gamble OTC Brands, 2012
Table 4.22 Procter & Gamble: OTC Pharmaceuticals Sales Forecast ($m), AGR (%), CAGR (%), 2011-2022
Table 4.23 Vicks US Formulations, 2012
Table 4.24 Vicks: Sales Forecast ($m), AGR (%), CAGR (%), 2011-2022
Table 4.25 Prilosec OTC: Sales Forecast ($m), AGR (%), CAGR (%), 2011-2022
Table 5.1 OTC Pharmaceuticals Revenues ($m) and Market Shares (%) in Leading National Markets, 2011
Table 5.2 Average Spending on OTC Pharmaceuticals ($) Per Adult (15+) Per Year and CAGR (%), 2011, 2017 and 2022
Table 5.3 OTC Pharmaceuticals: Overall Sales Forecasts ($m), AGRs (%) and CAGRs (%) for Leading National Markets, 2011-2017
Table 5.4 OTC Pharmaceuticals: Overall Sales Forecasts ($m), AGRs (%) and CAGRs (%) for Leading National Markets, 2018-2022
Table 5.5 US: OTC Sales Forecast ($m), AGR (%), CAGR (%), 2011-2022
Table 5.6 Japan: OTC Sales Forecast ($m), AGR (%), CAGR (%), 2011-2022
Table 5.7 Germany: OTC Sales Forecast ($m), AGR (%), CAGR (%), 2011-2022
Table 5.8 France: OTC Sales Forecast ($m), AGR (%), CAGR (%), 2011-2022
Table 5.9 UK: OTC Sales Forecast ($m), AGR (%), CAGR (%), 2011-2022
Table 5.10 Italy: OTC Sales Forecast ($m), AGR (%), CAGR (%), 2011-2022
Table 5.11 Spain: OTC Sales Forecast ($m), AGR (%), CAGR (%), 2011-2022
Table 5.12 China: OTC Sales Forecast ($m), AGR (%), CAGR (%), 2011-2022
Table 5.13 India: OTC Sales Forecast ($m), AGR (%), CAGR (%), 2011-2022
Table 6.1 Leading Pharma Companies and Number of Rx-to-OTC Switches, 2001-2011
Table 6.2 Recent and Future Cough, Cold and Allergy OTC Switches, 2012
Table 6.3 Recent and Future Analgesic OTC Switches, 2012
Table 6.4 Recent and Future Gastrointestinal OTC Switches, 2012
Table 6.5 Recent and Future Dermatological OTC Switches, 2012
Table 7.1 SWOT Analysis of the OTC Pharmaceutical Industry and Market, 2012
Table 7.2 World Population Forecasts, 2012, 2015, 2018 and 2022
Table 9.1 OTC Pharmaceuticals: Sales Forecasts by Therapeutic Category, 2011, 2013, 2016, 2019 and 2022

List Of Figures

LIST OF FIGURES

Figure 2.1 The OTC Pharmaceutical Supply Chain, 2012
Figure 3.1 Leading OTC Pharmaceutical Categories: Market Shares (%), 2011
Figure 3.2 The World OTC Pharmaceutical Market: Sales Forecast ($m), 2011-2022
Figure 3.3 Leading OTC Pharmaceutical Categories: Sales Forecasts ($m), 2011-2022
Figure 3.4 Leading OTC Drug Categories: Market Shares (%), 2012
Figure 3.5 Leading OTC Drug Categories: Market Shares (%), 2015
Figure 3.6 Leading OTC Drug Categories: Market Shares (%), 2018
Figure 3.7 Leading OTC Drug Categories: Market Shares (%), 2022
Figure 4.1 Leading OTC Pharmaceuticals Manufacturers' Market Shares (%), 2011
Figure 4.2 Tylenol: Sales Forecast ($m), 2011-2022
Figure 4.3 Nicorette (Johnson & Johnson): Sales Forecast ($m), 2011-2022
Figure 4.4 Panadol: Sales Forecast ($m), 2011-2022
Figure 4.5 GSK Smoking Cessation Brands: Sales Forecast ($m), 2011-2022
Figure 4.6 Bayer: OTC Pharmaceuticals Sales Forecast ($m), 2011-2022
Figure 4.7 Bayer Aspirin: Sales Forecast ($m), 2011-2022
Figure 4.8 Advil: Sales Forecast ($m), 2011-2022
Figure 4.9 Claritin OTC: Sales Forecast ($m), 2011-2022
Figure 4.10 Procter & Gamble: OTC Pharmaceuticals Sales Forecast ($m), 2011-2022
Figure 4.11 Vicks: Sales Forecast ($m), 2011-2022
Figure 4.12 Prilosec OTC: Sales Forecast ($m), 2011-2022
Figure 5.1 OTC Pharmaceuticals: Market Shares (%) of Leading National Markets, 2011
Figure 5.2 Average Spending Per Adult/Year on OTC Pharmaceuticals in Nine Leading National Markets, 2011-2022
Figure 5.3 US: OTC Sales Forecast ($m), 2011-2022
Figure 5.4 Japan: OTC Sales Forecast ($m), 2011-2022
Figure 5.5 Germany: OTC Sales Forecast ($m), 2011-2022
Figure 5.6 France: OTC Sales Forecast ($m), 2011-2022
Figure 5.7 UK: OTC Sales Forecast ($m), 2011-2022
Figure 5.8 Italy: OTC Sales Forecast ($m), 2011-2022
Figure 5.9 Spain: OTC Sales Forecast ($m), 2011-2022
Figure 5.10 China: OTC Sales Forecast ($m), 2011-2022
Figure 5.11 India: OTC Sales Forecast ($m), 2011-2022
Figure 7.1 World Population Forecast, 2012, 2015, 2018 and 2022
Figure 7.2 World Population Aged 65 or Over: Forecast, 2012, 2015, 2018 and 2022
Figure 7.3 Population Aged 65 and Over in Seven Leading Developed OTC Markets, 2011 and 2022
Figure 9.1 OTC Pharmaceuticals: Sales Forecasts by Therapeutic Category, 2011, 2013, 2016, 2019 and 2022

COMPANIES LISTED

Aaron Industries
Abbott
Actavis Group
Adams Respiratory Therapeutics [acquired by Reckitt Benckiser, 2008]
Alliance Boots
American Medical Association
AmerisourceBergen
AstraZeneca
AZ Tika [wholly owned by AstraZeneca]
Barr [acquired by Teva, 2008]
Bausch & Lomb
Bayer
Bayer Consumer Care
Boehringer Ingelheim
Bristol-Myers Squibb (BMS)
Cardinal Health
Celesio
Center for Drug Evaluation and Research (CDER)
Chattem
CNS [acquired by GSK, 2006]
Costco
CVS
Daiichi Sankyo
Dexcel Pharma
Dollar General
Dr. Reddy's Laboratories
Duramed
Eisai
European Medicines Agency (EMA, EMEA)
Federal Trade Commission [US]
Food and Drug Administration (FDA) [US]
Galpharm [acquired by Perrigo, 2008]
GlaxoSmithKline (GSK)
J.B. Chemicals and Pharmaceuticals
J.P. Morgan
Johnson & Johnson
Kowa Pharmaceuticals
Lion Corporation
LNK International
L'Oreal
Lupin
McKesson Corporation
McNeil Consumer Healthcare
Medicines and Healthcare Products Regulatory Agency (MHRA) [UK]
Menarini Group
Merck & Co.
Ministry of Health, Labour and Welfare (MHLW) [Japan]
Mylan Pharmaceuticals
Nichi-Iko Pharmaceutical Co.
Novartis
Nycomed
Ohm Laboratories
Paras Pharmaceuticals
Perrigo Company
Pfizer
PGT Healthcare
Phoenix
Proctor & Gamble
Public Citizen
Ranbaxy Laboratories
Ratiopharm
Reckitt Benckiser Group
Roche
Rohto
Roxane Laboratories
Sagmel [acquired by Bayer, 2008]
Sandoz
Sanofi
Santarus
Sato Pharmaceutical
Schering Plough
Sepracor
Somaxon Pharmaceuticals
SSL International
SSP Co.
Sun Pharmaceutical Industries
Taisho Pharmaceutical Co.
Takeda Pharmaceutical Company
Target Corporation
Teva Pharmaceutical Industries
Therapeutic Goods Administration (TGA) [Australia]
Torrent Pharmaceuticals
Tufts Center for the Study of Drug Development
University of the Sciences in Philadelphia
Walgreens
Walmart
Watson Pharmaceuticals
Wyeth [acquired by Pfizer, 2009]